Cargando…
Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry
The use of anticoagulant therapy in patients with pulmonary arterial hypertension (PAH) has been controversial for decades. Recommendations for anticoagulation in these patients are often derived from small, retrospective, and single centre studies without any placebo-controlled randomized study. Fu...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bloomsbury Qatar Foundation Journals
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220434/ https://www.ncbi.nlm.nih.gov/pubmed/25405178 http://dx.doi.org/10.5339/gcsp.2014.25 |
_version_ | 1782342734525235200 |
---|---|
author | Said, Karim |
author_facet | Said, Karim |
author_sort | Said, Karim |
collection | PubMed |
description | The use of anticoagulant therapy in patients with pulmonary arterial hypertension (PAH) has been controversial for decades. Recommendations for anticoagulation in these patients are often derived from small, retrospective, and single centre studies without any placebo-controlled randomized study. Furthermore, uncertainties exist regarding a number of issues such as patient selection, risk stratification for bleeding, the intensity of anticoagulation, appropriateness of anticoagulation in different types of PAH, and the potential use of new oral anticoagulants. Recently, the database of the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) has been analyzed to assess the effect of anticoagulation on the long-term outcome of patients with various forms of PAH. This analysis is the largest to date to assess anticoagulant therapy in PAH patients in a prospective design with long observation period. The results of COMPERA lend support to current recommendations for the use of anticoagulant therapy in patients with idiopathic PAH, but not in other forms of PAH. Also, the study confirmed the previously reported concern that anticoagulant therapy may be harmful in patients with scleroderma-associated PAH. |
format | Online Article Text |
id | pubmed-4220434 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Bloomsbury Qatar Foundation Journals |
record_format | MEDLINE/PubMed |
spelling | pubmed-42204342014-11-17 Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry Said, Karim Glob Cardiol Sci Pract Lessons from the Trials The use of anticoagulant therapy in patients with pulmonary arterial hypertension (PAH) has been controversial for decades. Recommendations for anticoagulation in these patients are often derived from small, retrospective, and single centre studies without any placebo-controlled randomized study. Furthermore, uncertainties exist regarding a number of issues such as patient selection, risk stratification for bleeding, the intensity of anticoagulation, appropriateness of anticoagulation in different types of PAH, and the potential use of new oral anticoagulants. Recently, the database of the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) has been analyzed to assess the effect of anticoagulation on the long-term outcome of patients with various forms of PAH. This analysis is the largest to date to assess anticoagulant therapy in PAH patients in a prospective design with long observation period. The results of COMPERA lend support to current recommendations for the use of anticoagulant therapy in patients with idiopathic PAH, but not in other forms of PAH. Also, the study confirmed the previously reported concern that anticoagulant therapy may be harmful in patients with scleroderma-associated PAH. Bloomsbury Qatar Foundation Journals 2014-06-18 /pmc/articles/PMC4220434/ /pubmed/25405178 http://dx.doi.org/10.5339/gcsp.2014.25 Text en © 2014 Said, licensee Bloomsbury Qatar Foundation Journals. This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Lessons from the Trials Said, Karim Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry |
title | Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry |
title_full | Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry |
title_fullStr | Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry |
title_full_unstemmed | Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry |
title_short | Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry |
title_sort | anticoagulation in pulmonary arterial hypertension: contemporary data from compera registry |
topic | Lessons from the Trials |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220434/ https://www.ncbi.nlm.nih.gov/pubmed/25405178 http://dx.doi.org/10.5339/gcsp.2014.25 |
work_keys_str_mv | AT saidkarim anticoagulationinpulmonaryarterialhypertensioncontemporarydatafromcomperaregistry |